NDC 50090-1745-01 - Losartan Potassium and Hydrochlorothiazide
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 50090-1745
- Requested NDC
- 50090-1745-01
- Package NDCs from labels
- 50090-1745-0, 50090-1745-1, 50090-1745-2, 50090-1745-01
- Manufacturer
- A-S Medication Solutions
- Effective date
- 2026-02-14
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Losartan Potassium and Hydrochlorothiazide - A-S Medication Solutions | A-S Medication Solutions | 2026-02-14 | Human Prescription Drug Label |
FDA-Initiated Inactive NDC Indexing#
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 50090-1745-0 | Losartan Potassium and Hydrochlorothiazide | 30 in 1 BOTTLE | TABLET, FILM COATED | 30 | 41 | |
| 50090-1745-1 | Losartan Potassium and Hydrochlorothiazide | 90 in 1 BOTTLE | TABLET, FILM COATED | 90 | 41 | |
| 50090-1745-2 | Losartan Potassium and Hydrochlorothiazide | 100 in 1 BOTTLE | TABLET, FILM COATED | 100 | 41 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 50090-1745 | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE TABLET, FILM COATED [A-S MEDICATION SOLUTIONS] | 38 | Current NDC, Legacy NDC, 3 package rows | 20241105_dc9512cf-db66-40e9-afcb-1d6a722772e8.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 50090-1745-0 | EA - Each | 50090-1745 | a7af2e3c-f12a-430b-9077-f9e506ff28f6 | 1 | 2018-10-11 |
| 50090-1745-1 | EA - Each | 50090-1745 | e3817854-fa12-449e-b7de-c240aad086f3 | 1 | 2018-10-11 |
| 50090-1745-2 | EA - Each | 50090-1745 | 7a366fca-d58e-4deb-a70e-471ca46697f5 | 1 | 2024-12-10 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| HERA SILKYSTAY FOUNDATION 22N1 | TITANIUM DIOXIDE | Amorepacific Corporation | 5eb415b3-b1ba-42b8-e063-6394a90a90d7 | 2026-10-25 | Warnings | 15FIX9V2JP |
| HERA SILKYSTAY FOUNDATION 21W1 | TITANIUM DIOXIDE | Amorepacific Corporation | 5eb42062-f298-5186-e063-6294a90ab043 | 2026-10-25 | Warnings | 15FIX9V2JP |
| HERA SILKYSTAY FOUNDATION 23C2 | TITANIUM DIOXIDE | Amorepacific Corporation | 5eb44e1b-b24b-6c83-e063-6394a90a4b52 | 2026-10-25 | Warnings | 15FIX9V2JP |
| HERA SILKYSTAY FOUNDATION 23W1 | TITANIUM DIOXIDE | Amorepacific Corporation | 5eb468db-3c38-922d-e063-6294a90adef8 | 2026-10-25 | Warnings | 15FIX9V2JP |
| HERA SILKYSTAY FOUNDATION 24N1 | TITANIUM DIOXIDE | Amorepacific Corporation | 5eb4b8ca-eced-b7ff-e063-6394a90aaefe | 2026-10-25 | Warnings | 15FIX9V2JP |
| HERA SILKYSTAY FOUNDATION 24O1 | TITANIUM DIOXIDE | Amorepacific Corporation | 5eb4f87a-b4dc-1aa5-e063-6294a90a2ec4 | 2026-10-25 | Warnings | 15FIX9V2JP |
| HERA SILKYSTAY FOUNDATION 25W1 | TITANIUM DIOXIDE | Amorepacific Corporation | 5eb50784-444e-3bf3-e063-6294a90aa618 | 2026-10-25 | Warnings | 15FIX9V2JP |
| Olmesartan Medoxomil and Hydrochlorothiazide | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | Umedica Laboratories USA Inc. | 55d6aee1-01ca-4791-8404-386664b4ab07 | 2026-10-23 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Olmesartan Medoxomil and Hydrochlorothiazide | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | Lifestar Pharma LLC | 9771066e-c05d-6a93-e053-2995a90a7e87 | 2026-10-23 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Hydrochlorothiazide | HYDROCHLOROTHIAZIDE | REMEDYREPACK INC. | f20fd735-30c7-4f89-8ceb-b6186646eea6 | 2026-10-22 | Warnings, Adverse reactions | 0J48LPH2TH |
| KARYNG Complete SPF Sunscreen Medium/Dark | SUNSCREEN | Karyng LLC | 335eee1e-ef1c-41da-e063-6294a90ac273 | 2026-10-20 | Warnings | 15FIX9V2JP |
| Triamterene and Hydrochlorothiazide | TRIAMTERENE AND HYDROCHLOROTHIAZIDE | Preferred Pharmaceuticals Inc. | 1fff8245-2b65-4ab1-aaa2-6bbbc6ac5fe8 | 2026-10-19 | Boxed warning, Adverse reactions | 0J48LPH2TH |
| olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide | OLMESARTAN MEDOXOMIL / AMLODIPINE BESYLATE / HYDROCHLOROTHIAZIDE | REMEDYREPACK INC. | 57ffeef7-bfa8-4f92-aadc-23cd00022607 | 2026-10-19 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| KARYNG Complete SPF Sunscreen Light/Medium | SUNSCREEN | Karyng LLC | 33596253-413d-fba3-e063-6394a90a39e4 | 2026-10-19 | Warnings | 15FIX9V2JP |
| Triamterene and Hydrochlorothiazide | TRIAMTERENE AND HYDROCHLOROTHIAZIDE | Preferred Pharmaceuticals Inc. | 5fc69fbf-c2d2-41ef-99bb-62a76ef74db2 | 2026-10-19 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| ALEX MD PHD Sheer Mineral Sunscreen | ZINC OXIDE, TITANIUM DIOXIDE | PHYSICIAN LABORATORIES INC | 8f64c4fa-92ee-4af0-ab1b-6c3673f9a622 | 2026-10-16 | Warnings | 15FIX9V2JP |
| ALEX MD PHD Tinted Mineral Sunscreen | ZINC OXIDE, TITANIUM DIOXIDE | PHYSICIAN LABORATORIES INC | 93873c34-5c72-43c8-b6c2-c65b596191d7 | 2026-10-16 | Warnings | 15FIX9V2JP |
| Telmisartan and Hydrochlorothiazide | TELMISARTAN AND HYDROCHLOROTHIAZIDE | Aurobindo Pharma Limited | 681dfb5c-fc5c-427e-81f6-4b4e934978a2 | 2026-10-16 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Losartan potassium | LOSARTAN POTASSIUM | REMEDYREPACK INC. | a959c71b-d658-4871-b303-073234b9fa84 | 2026-10-15 | Boxed warning, Warnings, Adverse reactions | 3ST302B24A |
| Solar Defense Non Tinted | TITANIUM DIOXIDE, ZINC OXIDE | HydroPeptide LLC | 45ec77c5-5ea1-0e51-e054-00144ff8d46c | 2026-10-14 | Warnings | 15FIX9V2JP |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.